Hemo Organic accepts resignation of Company Secretary Yukta Patel

0 min read | Published on 19 Sept 2026, 08:24 PM |Updated on 19 Sept 2026, 08:24 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Hemo Organic Limited accepted the resignation of Company Secretary Yukta Prakash Patel
The departure is effective from September 19, 2026, due to personal reasons
Disclosure made under Regulation 30 of SEBI LODR Regulations 2015
No material reasons for resignation cited other than personal factors

*this image is generated using AI for illustrative purposes only.

Hemo Organic Limited has accepted the resignation of Yukta Prakash Patel from her role as Company Secretary and Compliance Officer. The departure becomes effective immediately following the closure of business hours on September 19, 2026.

The company disclosed the change to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing references SEBI Circular No. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding detailed disclosures for such changes.

Resignation Details

Yukta Prakash Patel, who holds ICSI Membership No. A76482, tendered her resignation citing personal reasons. She confirmed in her resignation letter that there are no other material reasons for her departure beyond those stated.

Particulars	Details
Name	Yukta Prakash Patel
Designation	Company Secretary and Compliance Officer
Reason	Personal reasons
Effective Date	September 19, 2026

The Board of Directors accepted the resignation on the same date. Vishwambar Kameshwar Singh, Managing Director, authorized the disclosure on behalf of the company. The firm will proceed with filing the necessary forms with the Ministry of Corporate Affairs.

Will Hemo Organic Limited appoint an interim Company Secretary to ensure regulatory compliance during the transition period?

How might this leadership change impact the company's ongoing compliance with SEBI's Listing Obligations and Disclosure Requirements?

Are there any pending regulatory filings or audits that could be affected by the immediate departure of the Compliance Officer?

Hemo Organic appoints V S S B & Associates as statutory auditor for five years

1 min read | Published on 09 Sept 2026, 08:47 PM |Updated on 09 Sept 2026, 08:47 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Hemo Organic appoints M/s. V S S B & Associates as statutory auditor for five years
The new term runs from the conclusion of the 34th AGM to the 39th AGM
Outgoing auditors M/s M A A K & Associates completed their second term
All three ordinary resolutions passed unanimously at the September 8 AGM

*this image is generated using AI for illustrative purposes only.

Hemo Organic Limited shareholders appointed M/s. V S S B & Associates, Chartered Accountants, as the company's statutory auditor for a five-year term during its 34th annual general meeting on September 8, 2026.

The appointment follows the completion of the second term by the outgoing auditors, M/s M A A K & Associates, Chartered Accountants (FRN: 135024W). The new auditors, based in Ahmedabad and holding FRN 121356W, will serve from the conclusion of the 34th AGM until the conclusion of the 39th AGM.

AGM Outcomes

The virtual meeting, held on September 8, 2026, saw unanimous approval for all three ordinary resolutions proposed by the board. Shareholders voted via electronic means to ratify the financial position for the period ending September 1, 2026, which served as the record date.

In addition to the auditor appointment, shareholders approved:

Adoption of the annual audited financial statements and reports thereon.
Appointment of Mr Murlidhar Joshi (DIN: 09819849) as a director retiring by rotation.

Jitendra Parmar of Jitendra Parmar & Associates served as the scrutinizer, submitting his report on September 9, 2026.

Voting Participation

A total of 4,825 shareholders were on the register as on the record date. Only 21 shareholders attended the meeting through video conferencing or other audio-video means. This included two promoter group members and 19 public shareholders. No shareholders attended in person or through proxy.

Category	Shares Held	Votes Polled	Turnout %
Promoter Group	583,940	583,940	100%
Public Non-Institutions	2,881,960	6,715	0.233%
Total	3,465,900	590,655	17.0419%

Promoter entities held 583,940 shares and cast all their votes in favor of every resolution. Public non-institutional investors held 2,881,960 shares but polled only 6,715 votes, representing a turnout of 0.233%. No public institutional investors participated.

How might the appointment of M/s. V S S B & Associates influence Hemo Organic's financial reporting standards and regulatory compliance over the next five years?

What strategies could the board implement to address the critically low 0.233% turnout among public non-institutional shareholders in future AGMs?

Does the unanimous approval of resolutions despite minimal public participation raise any governance concerns regarding minority shareholder engagement?